Clinical Trials Directory

Trials / Recruiting

RecruitingNCT04677244

Echo-endoscopy Biopsy Impact on the Circulating Tumor Cell Level

Impact of Echo-endoscopy Biopsy on the Circulating Tumor Cell Level in the Portal System in Pancreatic Adenocarcinoma Management Care

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
42 (estimated)
Sponsor
Institut Paoli-Calmettes · Academic / Other
Sex
All
Age
40 Years – 85 Years
Healthy volunteers
Not accepted

Summary

The aim of this work is to evaluate the impact of endoscopic procedures on the circulating tumoral cells level in order to evaluate the potential effects of an endoscopic procedure in the management of pancreatic tumors.

Detailed description

The study will include 42 evaluable patients suspected of having pancreatic cancer and for whom an echo-endoscopic biopsy (EUS-FNA) and/or biliary drainage is planned. In these patients, a 6 ml blood sample will be taken from the portal vein before and after the echo-endoscopic biopsy of the pancreatic mass to determine: * the level of circulating tumor cells (CTC) per milliliter of blood, * cytological characteristics of CTCs (isolated, clustered, giant, and clustered including other cell types). A peripheral blood sample will also be taken to evaluate peripheral CTC levels and cytological characteristics before and after biopsy, as well as one month after biopsy. Patients will be evaluated every 6 months as part of their follow-up to assess the progression of their pathology and morbidity.

Conditions

Interventions

TypeNameDescription
PROCEDUREBlood sample in portal veinA 6 ml blood sample will be taken from the portal vein, before and after the echo-endoscopic biopsy of the pancreatic mass. The second sample will be taken after the biopsy if there is no bile drainage, or after bile drainage if indicated. The delay between the end of the biopsy procedure and the puncture will be 5 minutes. A 6 ml peripheral blood sample will also be taken before and after the endoscopic procedure.

Timeline

Start date
2021-11-11
Primary completion
2024-11-01
Completion
2025-11-01
First posted
2020-12-21
Last updated
2024-04-09

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT04677244. Inclusion in this directory is not an endorsement.